Clinical Trials Directory

Trials / Unknown

UnknownNCT06220994

the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia

The Gut Microbiome and Metabolomics Among Chronic Lower Extremities Threatening Ischemia Patients in China - a Prospective Observational Study

Status
Unknown
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Beijing Tsinghua Chang Gung Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Intestinal floras and their metabolites are involved in progressing metabolic and cardiovascular diseases. However, currently, articles related to the relationship between intestinal floras and atherosclerosis mainly focus on coronary atherosclerotic disease (CAD) population, or atherosclerosis model animals such as ApoE-/-, LDLR-/- high-fat diet mice, and there are few studies on Chronic limb-threatening ischemia (CLTI). CLTI and CAD have a similar pathological basis of atherosclerosis. It is unclear whether intestinal flora plays an essential role in the occurrence and development of CLTI. This project aims to explore the relation between microorganisms, metabolites, and CLTI.

Detailed description

This project aims to study the intestinal flora and its metabolites in patients with CLTI, explore whether CLTI patients and CAD patients have their own characteristic flora, analyze the microorganisms and metabolites markers of poor prognosis in patients with CLTI, and screen out the key differential bacteria and metabolites that inhibit the progress of CLTI, in order to provide new insights and research basis for the treatment of CLTI.

Conditions

Timeline

Start date
2021-11-15
Primary completion
2025-05-15
Completion
2025-05-15
First posted
2024-01-24
Last updated
2024-01-24

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06220994. Inclusion in this directory is not an endorsement.